Not SpaceX. Not Blue Origin. The Space Titan That Morgan Stanley Calls an Undervalued Launch Play.

Rocket Lab has a $2.36 billion backlog, including a 20-mission Synspective contract through 2031, and Morgan Stanley set a $105 price target versus a stated current share price of $75. The article highlights growth opportunities from the Neutron rocket and an acquisition of Iridium Communications, described as poised to close, while noting Rocket Lab’s $769 million trailing sales, roughly 50x price-to-sales ratio, lack of profitability, and cash burn. Its long-term upside depends on reliable Neutron launches and success in satellite services; the article cautions that its valuation is already high.

Analysis

The thesis hinges less on launch demand than on whether Rocket Lab can convert an unproven larger vehicle and any satellite-services expansion into durable, cash-generative economics. A multiyear backlog is not equivalent to near-term revenue or margin: delays can defer milestone receipts while fixed development costs continue. Neutron execution is therefore the key 1–3 month/next-launch catalyst; repeated schedule slippage or a failure to demonstrate reliable orbital operations would pressure both forecasts and the premium multiple. Over 6–18 months, successful execution could broaden the addressable market, but it also invites heavier capital needs and competition from SpaceX and established satellite operators.

Treat the asserted Iridium transaction as unverified from the supplied material. Before assigning Rocket Lab satellite-network value, confirm a definitive agreement, consideration and funding, required approvals, and each company’s filings. Even a completed acquisition would not instantly create a Starlink-like service: spectrum and regulatory rights, constellation investment, coverage, customer acquisition, and integration are separate hurdles. For Iridium holders, transaction terms and closing conditions—not Rocket Lab’s strategic narrative—would drive value.

Contrarian point: the premium may already price in successful Neutron scaling and a services option, while the article’s comparison with SpaceX’s total value says little about relative value. Conversely, a headline backlog or single favorable analyst view is not proof the shares are overvalued; execution evidence matters. No unqualified directional trade is justified without deal verification and updated cash, dilution, and launch-schedule data.

Key Decisions for Investors

• RKLB: Do not chase on the satellite-services claim alone. Set an alert for verified Neutron milestones and updated cash burn/share-count guidance; falsify the upside thesis on further material schedule slippage or weaker backlog conversion.
• Deal watch: Check Rocket Lab and Iridium filings for definitive terms, financing, approvals, and closing conditions before trading either name on the reported acquisition. No terms are supplied, so avoid an event-driven IRDM position for now.
• If RKLB rallies further without improved execution evidence, consider a defined-risk bearish options structure rather than an outright short; elevated valuation can make timing and borrow costly. Reassess if successful orbital operations and credible customer commitments materially de-risk Neutron.
• For a 6–18 month thesis, monitor cash consumption, dilution, launch cadence, and evidence of satellite-service economics. Backlog growth without improving conversion or funding visibility would weaken the risk/reward.